Literature DB >> 15913651

Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH.

Katja Conrath1, Cécile Vincke, Benoît Stijlemans, Joost Schymkowitz, Klaas Decanniere, Lode Wyns, Serge Muyldermans, Remy Loris.   

Abstract

Heavy chain only antibodies of camelids bind their antigens with a single domain, the VHH, which acquired adaptations relative to classical VHs to function in the absence of a VL partner. Additional CDR loop conformations, outside the canonical loop structures of VHs, broaden the repertoire of the antigen-binding site. The combined effects of part of the CDR3 that folds over the "former" VL binding site and framework-2 mutations to more hydrophilic amino acids, enhance the solubility of VHH domains and prevent VL pairing. cAbAn33, a VHH domain specific for the carbohydrate moiety of the variant surface glycoprotein of trypanosomes, has a short CDR3 loop that does not cover the former VL binding site as well as a VH-specific Trp47 instead of the VHH-specific Gly47. Resurfacing its framework-2 region (mutations Tyr37Val, Glu44Gly and Arg45Leu) to mimic that of a human VH restores the VL binding capacity. In solution, the humanised VHH behaves as a soluble, monomeric entity, albeit with reduced thermodynamic stability and affinity for its antigen. Comparison of the crystal structures of cAbAn33 and its humanised derivative reveals steric hindrance exerted by VHH-specific residues Tyr37 and Arg45 that prevent the VL domain pairing, whereas Glu44 and Arg45 are key elements to avoid insolubility of the domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913651     DOI: 10.1016/j.jmb.2005.04.050

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  29 in total

1.  Dual beneficial effect of interloop disulfide bond for single domain antibody fragments.

Authors:  Jochen Govaert; Mireille Pellis; Nick Deschacht; Cécile Vincke; Katja Conrath; Serge Muyldermans; Dirk Saerens
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

2.  Protein production in Yarrowia lipolytica via fusion to the secreted lipase Lip2p.

Authors:  Thomas Hofmeyer; Siyavuya Ishmael Bulani; Julius Grzeschik; Simon Krah; Bernhard Glotzbach; Christina Uth; Olga Avrutina; Michael Brecht; Hans Ulrich Göringer; Petrus van Zyl; Harald Kolmar
Journal:  Mol Biotechnol       Date:  2014-01       Impact factor: 2.695

3.  High affinity anti-inorganic material antibody generation by integrating graft and evolution technologies: potential of antibodies as biointerface molecules.

Authors:  Takamitsu Hattori; Mitsuo Umetsu; Takeshi Nakanishi; Takanari Togashi; Nozomi Yokoo; Hiroya Abe; Satoshi Ohara; Tadafumi Adschiri; Izumi Kumagai
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

4.  Production, crystallization and X-ray diffraction analysis of two nanobodies against the Duffy binding-like (DBL) domain DBL6ℇ-FCR3 of the Plasmodium falciparum VAR2CSA protein.

Authors:  Anneleen Vuchelen; Els Pardon; Jan Steyaert; Benoît Gamain; Remy Loris; Nico A J van Nuland; Stéphanie Ramboarina
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-02-22

5.  Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis.

Authors:  Oleg V Kovalenko; Andrea Olland; Nicole Piché-Nicholas; Adarsh Godbole; Daniel King; Kristine Svenson; Valerie Calabro; Mischa R Müller; Caroline J Barelle; William Somers; Davinder S Gill; Lidia Mosyak; Lioudmila Tchistiakova
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

6.  Generation of heavy-chain-only antibodies in mice.

Authors:  Rick Janssens; Sylvia Dekker; Rudi W Hendriks; George Panayotou; Alexandra van Remoortere; John Kong-a San; Frank Grosveld; Dubravka Drabek
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

7.  Analysis and modeling of the variable region of camelid single-domain antibodies.

Authors:  Aroop Sircar; Kayode A Sanni; Jiye Shi; Jeffrey J Gray
Journal:  J Immunol       Date:  2011-04-27       Impact factor: 5.422

Review 8.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.

Authors:  Weizao Chen; Rui Gong; Tianlei Ying; Ponraj Prabakaran; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Curr Drug Discov Technol       Date:  2014-03

Review 10.  Prospects of Neutralizing Nanobodies Against SARS-CoV-2.

Authors:  Fangfang Chen; Zhihong Liu; Fan Jiang
Journal:  Front Immunol       Date:  2021-05-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.